NRX Pharmaceuticals, Inc. (NRXP) stock
NRXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.45+0.30 (+13.95%)
Close on Nov 17, 2026Market cap $106.08MP/E –Yield –
NRX Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
NRX Pharmaceuticals's total assets was $34.16M at Jun 30, 2026. For fiscal 2025 it was $12.96M, up 254.9% from the year before. The highest annual figure on record is $70.80M in fiscal 2018.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.96M | +254.9% |
| FY2024 | Dec 31, 2024 | $3.65M | -50.1% |
| FY2023 | Dec 31, 2023 | $7.32M | -71.7% |
| FY2022 | Dec 31, 2022 | $25.82M | -21.1% |
| FY2021 | Dec 31, 2021 | $32.73M | +1012.8% |
| FY2020 | Dec 31, 2020 | $2.94M | -90.8% |
| FY2019 | Dec 31, 2019 | $32.07M | -54.7% |
| FY2018 | Dec 31, 2018 | $70.80M | +1.8% |
| FY2017 | Dec 31, 2017 | $69.57M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $34.16M | +606.1% |
| Q1 FY2026 | Mar 31, 2026 | $11.90M | +56.8% |
| Q4 FY2025 | Dec 31, 2025 | $12.96M | +254.9% |
| Q3 FY2025 | Sep 30, 2025 | $15.00M | +236.1% |
| Q2 FY2025 | Jun 30, 2025 | $4.84M | -8.1% |
| Q1 FY2025 | Mar 31, 2025 | $7.59M | +100.4% |
| Q4 FY2024 | Dec 31, 2024 | $3.65M | -50.1% |
| Q3 FY2024 | Sep 30, 2024 | $4.46M | -66.0% |
| Q2 FY2024 | Jun 30, 2024 | $5.26M | -73.4% |
| Q1 FY2024 | Mar 31, 2024 | $3.79M | -82.6% |
| Q4 FY2023 | Dec 31, 2023 | $7.32M | -71.7% |
| Q3 FY2023 | Sep 30, 2023 | $13.11M | -47.2% |
| Q2 FY2023 | Jun 30, 2023 | $19.81M | -38.9% |
| Q1 FY2023 | Mar 31, 2023 | $21.78M | -50.0% |
| Q4 FY2022 | Dec 31, 2022 | $25.82M | -21.1% |
| Q3 FY2022 | Sep 30, 2022 | $24.82M | -45.1% |
| Q2 FY2022 | Jun 30, 2022 | $32.43M | +74.9% |
| Q1 FY2022 | Mar 31, 2022 | $43.60M | +623.3% |
| Q4 FY2021 | Dec 31, 2021 | $32.73M | +1012.8% |
| Q3 FY2021 | Sep 30, 2021 | $45.25M | +650.2% |
| Q2 FY2021 | Jun 30, 2021 | $18.55M | +195.5% |
| Q1 FY2021 | Mar 31, 2021 | $6.03M | -3.9% |
| Q4 FY2020 | Dec 31, 2020 | $2.94M | -90.8% |
| Q3 FY2020 | Sep 30, 2020 | $6.03M | -85.5% |
| Q2 FY2020 | Jun 30, 2020 | $6.28M | -87.5% |
| Q1 FY2020 | Mar 31, 2020 | $6.27M | -91.3% |
| Q4 FY2019 | Dec 31, 2019 | $32.07M | -54.7% |
| Q3 FY2019 | Sep 30, 2019 | $41.69M | -40.4% |
| Q2 FY2019 | Jun 30, 2019 | $50.10M | -28.1% |
| Q1 FY2019 | Mar 31, 2019 | $71.71M | +3.1% |
| Q4 FY2018 | Dec 31, 2018 | $70.80M | +1.8% |
| Q3 FY2018 | Sep 30, 2018 | $69.89M | – |
| Q2 FY2018 | Jun 30, 2018 | $69.70M | – |
| Q1 FY2018 | Mar 31, 2018 | $69.55M | – |
| Q4 FY2017 | Dec 31, 2017 | $69.57M | – |
See a number that looks wrong?